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Glioblastoma (GBM) is a highly angiogenic malignancy that is resistant to standard therapy; neo-formed vessels of
this aggressive malignancy are thought to arise by sprouting of pre-existing brain capillaries. However, the
conventional anti-angiogenic therapy, which seemed promising initially, shows transitory and incomplete efficacy.
The discovery of vasculogenic mimicry (VM) has offered a new horizon for understanding tumor vascularization. VM
is a tumor cell-constituted, matrix-embedded fluid-conducting meshwork that is independent of endothelial cells
and is positively correlated with poor prognosis. Therefore, a better understanding of GBM vasculature is needed to
optimize anti-angiogenic therapy. This review focuses on the signaling molecules and cascades involved in VM in
relation to ongoing glioma research, as well as the clinical translational advances in GBM that have been offered by
the development of optimized anti-angiogenesis treatment modalities.
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Glioblastoma (GBM) is the most common and lethal
malignant brain tumor in adults. It is an extraordinarily
aggressive malignancy characterized by extensive micro-
vascular proliferation and is highly resistant to intensive
combination therapies. The prognosis for GBM patients
is extremely poor despite the use of comprehensive
treatment involving gross tumor resection, chemother-
apy and/or radiotherapy, with an average life expectancy
of 12 to 15 months once diagnosed [1,2].
GBM is one of the most vascularized tumors, and its
poor prognosis primarily results from its invasive prop-
erties. Indeed, an accepted tenet underlying tumor sur-
vival is that a blood supply is required to sustain growth
and invasion [3]. The neoplastic angiogenesis research
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creativecommons.org/publicdomain/zero/1.0/enthusiastic preclinical trials, which ultimately reaped
disappointing clinical results [4]. Thus, investigators ac-
cepted that tumor perfusion mechanisms are much
more sophisticated than we previously realized [2].
The newly discovered vascular network structure, vas-
culogenic mimicry (VM), was first described and defined
by Maniotis et al. for malignant melanoma in 1999 [5].
The discovery of VM simultaneously sparked intensive
controversy [6] and brought a new vision to tumor ther-
apy. VM is defined by a fluid-conducting, matrix-
embedded meshwork that is independent of endothelial
cells (ECs), but instead is formed by certain types of
tumor cells through their acquirement of plasticity to
mimic endothelial function [7]. Since the discovery of
VM, cumulative studies have contributed new insights
into the underlying molecular pathways supporting its
existence in a variety of non-melanoma aggressive tu-
mors [8-13], including GBM [14]. CD34 or CD31 and
PAS dual-staining have been applied to visualize the EC-
free, matrix-rich morphological pattern of VM [5,8-14];
and immunohistochemistry and microarray analysis have
been applied to identify its undifferentiated, embryonic-
like phenotype [5,7,14]. Two distinctive VM types–
tubular type [15] and patterned matrix type [14,16]–havele distributed under the terms of the Creative Commons Attribution License
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vast field, we now appreciate that the simplistic model of
sprouting angiogenesis is far too limited to describe the
complex tumor vasculature. There are several other par-
adigms reported in addition to VM (Figure 1), including
vascular co-option, vascular intussusception, bone mar-
row-derived vasculogenesis and cancer stem-like cell-de-
rived vasculogenesis [3]. For glioma, the phenomenon of
VM is associated with high grades of tumor invasiveness
and poor prognosis [1,17]. As an alternative to trad-
itional anti-angiogenic therapy, the identification of mol-
ecules and signaling pathways relating to VM may offer
potential therapeutic targets to improve treatment [18].
In this review, we summarize the current progress in
understanding the molecular mechanisms revealed by
ongoing glioma VM research and discuss potential VM-
targeting strategies for the future development of GBM
therapies.
Functional characterization of VM
Tumors depend on an adequate blood supply for growth
and metastasis [2,3]; therefore, intratumoral microvesselFigure 1 Mechanisms of tumor vascularization. The different mechanisms
sprouting angiogenesis: sprouting of pre-existing brain capillaries through pro
cell-constituted, matrix-embedded fluid-conducting meshwork; (C) vascular c
intussusception: internal division of the preexisting capillary plexus; (E) bone m
precursors (EPCs) to form new vessels; (F) cancer stem-like cell-derived vasculdensity is assessed as a biomarker for tumor progression
and is considered a valuable prognostic indicator [19].
However, clinical trials have shown that some tumors
with low intratumoral microvessel density have poor
prognosis, and conventional anti-angiogenic results are
not consistently predictive. The inconsistency between
theory and practice suggests that alternative vascular
mechanisms exist, which was the basis for proposing
VM as a new topic of research [2].
The presence of characteristic VM structures in tumor
tissues is associated with poor clinical outcome, suggesting
that VM contributes functionally to tumor progression.
Blood circulation demonstrated by confocal indocyanine
green angiography revealed that VM patterns are not part
of the EC-lined vascular system. Fluid enters these chan-
nels through leakage and circulates within the VM net-
work rather than accumulating in a pool [20].
In addition, microarray analysis illustrated that tumor
cells involved in the VM structure convert to a dediffer-
entiated, embryonic-like phenotype, which appears to be
multipotent to act as either ECs or common tumor cells.
Moreover, the co-localization of tumor cells and ECsof tumor vascularization are depicted in the figure. These include: (A)
liferation and migration of local ECs; (B) vasculogenic mimicry: tumor
o-option: tumor cells grow along pre-existing blood vessels; (D) vascular
arrow-derived vasculogenesis: recruitment of circulating endothelial
ogenesis: transdifferentiation of CSCs into ECs to form new vessels.
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vessels [16]) indicates a direct or indirect physical con-
nection between endothelial vessels and VM networks.
Biological phenomena of Glioma stem-like cells
(GSCs) related to VM
Tumor cells capable of VM formation exhibit high plasti-
city indicative of a multipotent phenotype that resembles
embryonic stem cells. This phenomenon is confirmed for
cancer stem cells (CSCs). A simple recapitulation of the
CSC theory is as follows: genetically dysregulated tumor
cells are embryonic-like, therefore “plastic”, and therefore
capable of expressing vascular-like phenotypes [16].
Though specific criteria for the identification of CSCs
have not been established, screening and enrichment of
CSCs prospectively in a series of malignancies has identi-
fied stem cell biomarkers such as CD133 and Nestin,
which are also expressed in GSCs [21,22]. CSCs can be
enriched by the use of anti-CD133 antibodies or through
the generation of neurospheres in a certain culture condi-
tion, mostly serum-free media containing epidermal
growth factor and basic fibroblast growth factor [23]; and
GSC screening undergoes similar procedures. As for the
origins of GSCs, in addition to the multistep mutations of
normal stem cell genomes, GSCs might also be derived
partly due to dedifferentiation via the process of epithelial-Figure 2 The three stages of tumor blood supply pattern. The possible conn
different stages of a continuous process–(A) VM channels, (B) mosaic vessels
proliferation acts as a trigger point to anther tumor blood supply cycle.mesenchymal-transition (EMT), a process about regaining
dedifferentiated phenotypes and mesenchymal features
[24]. Therefore, GSCs may be considered a bridge be-
tween EMTand VM formation.
Similar to normal neural stem cells, GSCs possess the
capacity of self-renewal and multi-lineage differentiation;
however, aberrant gene regulation confers their tumori-
genicity. GSCs participate in VM formation by interact-
ing with the vascular niche to shape the proper tumor
microenvironment and by differentiating into EC-like
tumor cells to constitute VM structure. The cells derived
from GSCs present multi-phenotype features of different
lineages, such as neural cells and mural cells, thus effect-
ively mimicking the microcirculatory system. The tumor
vasculature of GSCs in an incomplete stage is thought to
be formed by VM channel [23], consistent with the three
stages of tumor blood supply pattern proposed by Zhang
et al. [25], namely VM channels, mosaic vessels and the
endothelium-dependent vessels (Figure 2).
Signaling cascades involved in VM
There are two main aspects that underlie the formation
of VM, i.e. highly plastic tumor cells and the tumor
microenvironment. The tumor cells lining the vasculature
display an undifferentiated embryonic-like biological and
molecular phenotype [26], suggesting the involvement ofection between VM channels and the endothelium-dependent vessels:
and (C) the endothelium-dependent vessels. Figure 2(D)–tumor
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the capacity of self-renewal, multi-lineage differentiation,
tumor initiation and resistance to chemo- or radio-therapy
[27]. Additionally, the tumor microenvironment is a critical
factor that conventional tumor cell-targeted therapy fails to
take into account. Changes in the extracellular micro-
environment may persist after removal or destruction
of an aggressive tumor, thus resulting in the recurrence
or continuance of certain tumors [28]. The over-expres-
sion of VEGFR-2 [21,26,29], EphA2 [30], VE-cadherin
[31], MMPs and TGF-β [32], among other molecules,
have been demonstrated to be closely associated with
vasculature formation. Hypoxia, which can be induced
by Bevacizumab therapy [33], represents an additionally
factor that might partially activate remodeling of the
extracellular microenvironment as a result of oxygen-
glucose deprivation.
The multipotent phenotype underlying VM is sup-
ported by a complex network of potential signaling
pathways, and an increasing number of studies have
been conducted to illustrate the fundamental mecha-
nisms in order to establish new treatment regimens.
We present some of the signaling pathways attributed
to VM formation in GBM (Figure 3, Table 1) accordingFigure 3 Schematic model of signaling pathways implicated in glioma vas
condition of hypoxia. Only signaling molecules which have been specifical
molecule inhibitors are depicted – demonstrating their ability to directly or
(purple), embryonic/stem cell (red), and hypoxia signaling pathways (blue).
overlap between major VM signaling pathways demonstrated coordinatedto their association with the embryonic/stem cell pheno-
type (section Stem cell pathway of GBM), the glioma
microenvironment (section Glioma microenvironment-
related signaling pathways) and hypoxic conditions
(section Hypoxia-related mechanism of VM).
Stem cell pathway of GBM
Tumor cells capable of VM formation exhibit a high
plasticity indicative of a multipotent phenotype resem-
bling embryonic stem cells. The in vitro tubular forma-
tion capacity and unique gene expression signature of
highly invasive melanoma cells suggests that tumor cell
VM activity is associated with distinctive genetic dysreg-
ulation [5]. Microarray analysis of VM-positive tissues
revealed increased expression of genes associated with
an undifferentiated embryonic-like phenotype [7]. GSCs
participate in VM formation in several ways: they inter-
act with the vascular niche to shape the proper tumor
microenvironment [26,32,34] and differentiate into EC-
like tumor cells to constitute VM structure [21,22]. Sev-
eral molecules associated with anaplastic properties of
tumor cells are over-expressed in CSCs and are associ-
ated with VM formation, including transforming growth
factorβ (TGFβ) [32], Nodal [34], and vascular endothelialculogenic mimicry (VM). The whole VM process proceeds under the
ly modulated using small inhibitory RNAs, blocking antibodies or small
indirectly affect VM, and are categorized as microenvironment
There are no specific boundary lines between the three parts and
work of these pathways.
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Nodal are members of the TGFβ superfamily and are
discussed in section The TGFβ signaling pathway below,
while VEGFR-2 is discussed in section The vascular
endothelial growth factor receptor-2 (VEGFR-2)/Flk-1
pathway on the basis of its more well-established role in
affecting the tumor microenvironment.
The TGFβ signaling pathway
The TGFβ superfamily of growth factors is a group of
ubiquitous multifunctional cytokines that regulate a
plethora of cellular activities, including proliferation, dif-
ferentiation, migration and survival. Both TGFβ and
Nodal are critical members of this family [35]. TGFβ is
named after its function in inducing EMT [34], a process
whereby fully differentiated epithelial cells divert to a
dedifferentiated state and acquire mesenchymal features.
TGFβ regulates two different aspects of VM formation:
the maintenance of the undifferentiated embryonic state
of stem cell via EMT [36] and the induction of tubular
formation through modulation of the tumor microenvir-
onment. Studies of breast cancer and melanoma show
that TGFβ stimulates tubular formation by regulatingMMP expression in epithelial tumors [37,38]. Thus,
TGFβ enhances or reduces the activity of the MMP-lam-
inin 5γ2 chain signaling pathway (discussed further in
section The MMP-laminin 5γ2 chain signaling pathway).
Similar regulatory mechanisms have been detected in
GBM [32].
Ling, et al. demonstrated that TGFβ levels correspond
with glioma malignancy in vitro. Plasmid transfection of
TGFβ mRNA activates the dose-dependent expression
of VM-related molecules in glioma cell lines as assessed
by RT-PCR, and the activity of MMP2 and MMP9 as
assessed by gelatin zymography. Furthermore, inhibition
of TGFβ results in a decline in both the quantity and ac-
tivity of MT1-MMP, which in turn reduces MMP2 acti-
vation, thereby impairing tubular formation. EphA2 was
not modulated in response to TGFβ regulation in this
study, and VE-cadherin (CDH5), which can be induced
by potent down-regulation of TGFβ through EMT, was
detectably absent [32]. This is inconsistent with the role
for VE-cadherin in VM reported by Mao, et al. [31]. A
possible explanation for this discrepancy involves the
use of glioma cell lines versus GSCs. The putative roles
for VE-cadherin and EphA2 in regulating the glioma
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(section The VE-cadherin (CDH5) and EphA2 pathways).
Nodal, a potent embryonic morphogen in the TGFβ
superfamily, is a biomarker that normally loses expres-
sion during the differentiate process, but becomes aber-
rantly re-expressed in highly aggressive tumors. Nodal
contributes to tumor progression and plasticity through
a variety of mechanisms [39]. Though the role for Nodal
has not precisely been demonstrated for GBM, the acti-
vation of Nodal expression by TGFβ has been shown to
promote glioma cell growth [34]. Given the above infor-
mation, we can presume that both the activation of
EMT and the TGFβ-induced expression of MMPs and
Nodal play a role in VM formation.
Glioma microenvironment-related signaling pathways
Pathways known to modulate the glioma microenviron-
ment include the vascular endothelial growth factor recep-
tor-2 (VEGFR-2)/Flk-1 pathway (section The vascular
endothelial growth factor receptor-2 (VEGFR-2)/Flk-1
pathway), VE-cadherin (CDH5) and EphA2 pathways (sec-
tion The VE-cadherin (CDH5) and EphA2 pathways), the
RTK/PI3K/Akt/mTOR signaling pathway (section The
RTK/PI3K/Akt/mTOR signaling pathway), and the MMP-
laminin 5γ2 chain signaling pathway (section The MMP-
laminin 5γ2 chain signaling pathway). The potential role
of other related molecules in determining the glioma
microenvironment in VM is discussed in section Other
molecules that regulate the glioma microenvironment in
VM.
The vascular endothelial growth factor receptor-2
(VEGFR-2)/Flk-1 pathway
VEGFR-2 has emerged as an essential angiogenic medi-
ator of signaling cascades induced by vascular endothe-
lial growth factor (VEGF). High levels of both VEGFR-2
and VEGF are co-expressed during angiogenesis. The
VEGF-VEGFR pathway and its downstream molecular
cascades are thought to activate both traditional angio-
genesis and VM in some aggressive tumors [18,40].
VEGFR-2, a receptor tyrosine kinase, is the earliest dif-
ferentiation marker for ECs. Its expression in adults is
normally restricted primarily to ECs, but is up-regulated
transiently during angiogenesis [29]. VEGFR-2 has been
reported to be over-expressed in GBM by GSCs at both
the mRNA and protein level. Once activated by VEGF,
this signaling pathway mediates chemotaxis, self-renewal,
tumorigenicity, tubule formation and over-expression of
critical VM markers [26]. VEGFR-2 phosphorylation at
specific tyrosine residues in an intracellular kinase domain
in its C-terminus subsequently activates down-stream
intracellular signaling molecular cascades, including the
focal adhesion kinase (FAK) and mitogen-activated pro-
tein kinase (MAPK)- extracellular signal-regulated proteinkinases 1 and 2 (ERK1/2) cascades, and smooth muscle
actin (SMa) expression. Activation of the FAK and
MAPK-ERK1/2 signaling pathways then mediate cell pro-
liferation, migration, and tubule formation [26]. However,
these events do not require VEGF stimulation in GBM-
derived tumor cell lines [26,29], which might partially be
explained by the constitutive phosphorylation of VEGFR-2
in GSCs [26]. VEGFR-2 also may be activated indirectly
by other factors in the tumor microenvironment, either
through binding to membrane-associated integrins or by
coordinate induction of integrins, leading to increased
VEGFR-2 activation [26]. Follow-up studies using animal
tumor models also validate the indispensable role of
VEGFR-2, which is independent of VEGF and regulates
mural-like tumor cell-associated VM in GBM [21,26].
The VE-cadherin (CDH5) and EphA2 pathways
VE-cadherin, a member of the cadherin-family, is a
transmembrane glycoprotein that is thought to be spe-
cifically expressed in ECs. VE-cadherin promotes homo-
typic cell-cell interactions and was one of the first
molecules identified as an important player in VM for
melanoma [41]. The Eph family is the largest family of
receptor tyrosine kinases (RTKs) and regulates cell pro-
liferation, migration and angiogenesis. Similar to the
findings for melanoma [42], both VE-cadherin and EphA2
are expressed at higher levels in VM-positive glioma than
VM-negative glioma, and the expression of these genes
correlates with the glioma grade and is known to be re-
quired for VM network formation [30,31,43]. Low expres-
sion levels in glioma cell lines that are incapable of VM
formation further indicates a role for these molecules in
VM [31,32]. Additionally, knockdown of these genes with
short hairpin RNA causes a predominant decrease in VM
formation [31,42]. For hypoxia-induced VM, VE-cadherin
is up-regulated by hypoxia-inducible factor (HIF) 2α and
1α through direct binding to the VE-cadherin promoter
[31]. Furthermore, EphA2 over-expression couples with
reduced miR-26b expression, properly speaking, miR-26b
down-regulates the levels of endogenous EphA2 protein
by binding to a specific microRNA response element in its
3’UTR [30]. In 2006, Hess et al. demonstrated that in VM-
positive melanoma, VE-cadherin co-localizes with EphA2
at areas of cell-cell contact, and these two molecules inter-
act either directly or indirectly during the process of VM
formation [42]. VE-cadherin regulates EphA2 activity by
mediating its auto-phosphorylation through interaction
with its membrane bound ligand, Ephrin-A1. Phosphory-
lated EphA2 subsequently regulates the phosphoinositide
3-kinase (PI3K) and FAK [44,45] pathways, thus activating
the PI3K-MMP-laminin 5γ2 chain signaling pathways and
related intracellular signaling cascades. Whether a similar
pathway of regulation occurs in GBM awaits further
verification.
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The mutant RTK/PI3K/Akt/mTOR pathway is the most
frequently deregulated signaling cascade in GBM and
regulates various cellular processes such as proliferation,
growth, apoptosis, and cytoskeletal rearrangement [46].
This pathway has been accepted as a novel genetic target
for acquired glioma resistance [45,47,48].
RTKs are the largest group of the enzyme linked receptor
families, which possess an N-terminal extracellular ligand-
binding domain, a single anchoring transmembrane-helix,
and a cytosolic C-terminal region that contains the cata-
lytic domain [46]. In glioma, EGFR is one of the most
prominent members [46,47]. PI3K is a cytoplasmic lipid
kinase consisting of a regulatory subunit, p85, and a cata-
lytic subunit, p110. Combination of p85 and the RTK re-
sults in the activation of catalytic subunit (p110), which
then catalyzes the phosphorylation of PI 3,4-bisphosphate
(PIP2) into 3,4,5-triphosphate (PIP3) [46]. PIP3 in turn
activates phosphoinositide-dependent kinase-1 (PDK1),
which subsequently activates Akt by phosphorylating spe-
cific amino acid sites. Activated Akt regulates a series of
downstream molecules such as mTOR, which controls a
variety of cellular functions [46]. Deficiency of PTEN and
related regulators in glioma, which serve as negative regu-
lators of PIP2 and PIP3, promotes tumor invasiveness [49].
Conversely, targeting of the mutant RTK/PI3K/Akt/mTOR
signaling pathway leads to consistent reduction in the inva-
sion and migration by VM channels in U251 glioma cells
[49]. In concert with these results, VM-related molecules
such as EphA2 and MMPs also show a corresponding re-
duction [49]. These findings suggest that the aberrant
RTK/PI3K/Akt/mTOR pathway plays a role in GBM VM
formation.
The MMP-laminin 5γ2 chain signaling pathway
The laminin 5γ2 chain is the main component of the
basal membrane, which can be degraded by MMPs. The
over-expression of MMPs in several malignant tumors
such as aggressive melanoma [50] and GBM [17,32] can
promote tumor invasion and migration. In GBM cell
lines [32] and GBM samples [17], MMPs showed a
positive correlation with VM formation.
The MMP-laminin5γ2 chain pathway has been sug-
gested as a common downstream signaling pathway of
several molecular cascades. The MMP-laminin 5γ2 chain
and other signaling regulators associated with VM
(TGFβ [32], VE-cadherin, EphA2, PI3K [42] etc.) are co-
ordinately over-expressed in a number of malignancies
including GBM [32] and aggressive melanoma [50].
MMP transcription is regulated by upstream regulators
such as TGFβ [32]. When activated by upstream mole-
cules, MT1-MMP converts proMMP2 to active MMP2.
Both MT1-MMP and MMP2 promote the cleavage of
the laminin 5γ2 chain into promigratory γ2′and γ2xfragments, which in turn stimulate migration, invasion,
and VM formation [32]. MT1-MMP siRNA promotes a
sharp decrease in the cleavage of the laminin 5γ2 chain
and VM formation [32]. Thus, the MMP-laminin5γ2
chain pathway may serve as the final executor of VM
formation for several molecular cascades.
Other molecules that regulate the glioma microenvironment
in VM
Cyclo-oxygenase-2 (COX-2), an inducible isoform of the
prostaglandin synthesis enzyme cyclooxygenase, shows a
positive association with VM channel formation [51].
Pathophysiological factors induce the expression of this
enzyme, which is not constitutively expressed in physio-
logical states. COX-2 has been shown to promote cell
survival, proliferation, and angiogenesis and prohibit
apoptosis, all of which are involved in tumor progression
[51]. Recent reports have revealed that highly invasive
human glioma cell lines exhibit higher COX-2 expres-
sion with vascular channels formation when cultured on
three-dimensional Matrigel, whereas non-invasive cell
lines do not exhibit this biological phenomenon. These
results are supported by studies of human glioma speci-
mens [17]. Inhibition of COX-2 with Celecoxib or spe-
cific siRNAs caused a noteworthy reduction in VM
formation, suggesting that COX-2 functions in the for-
mation of VM structures.
Other molecules potentially associated with VM for-
mation in GBM include microRNA-9 (miR-9) and
Galectin-1 (Gal-1). MiR-9, a tissue-specific microRNA in
the central nervous system, inhibits VM formation of
glioma cell lines by suppressing Stathmin expression
[52]. Gal-1 is regulated by a brain-expressed X-linked
gene and is reported to be associated with VM in vitro
and in vivo in an oligodendroglioma model [53]; there-
fore, a similar role for Gal-1 might characterize GBM.
Though the exact mechanisms of these molecules are
not well elucidated, it is likely that these so-called VM-
related pathways co-operate with other pathways in the
remodeling of the VM extracellular microenvironment.
Hypoxia-related mechanism of VM
Hypoxia may potentially be the earliest inducer of VM
and influences VM throughout the process. Hypoxia is
more easily detectable in more invasive and rapidly pro-
liferating tumors. Furthermore, the role for hypoxia in
VM is supported by findings that in vitro hypoxic condi-
tions can lead to VM formation [31]. Induction of VM
formation in the absence of oxygen may explain the
poor outcome of conventional anti-angiogenic therapy
in aggressive melanoma [2]. As a hallmark of most
tumors, hypoxia participates in different pathways to
maintain a stem cell-like phenotype, regulate cellular
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resistance to apoptosis, angiogenesis and VM [18].
During VM formation in GBM, HIF2α and 1α regulate
VE-cadherin expression by directly interacting with hyp-
oxia responsive elements (HREs) in its promoter [31];
however, in aggressive melanoma, though hypoxia in-
duces VM via VE-cadherin, VE-cadherin is up-regulated
by Bcl-2 rather than HIFs [54]. Moreover, during the
process of GSC generation and transdifferentiation to-
wards tubular formation in vitro, hypoxia offers an in-
dispensable condition for GSCs to differentiate into a
group of specialized cells that express specific bio-
markers [55], many of which are thought to be pro-
moted by HIFs [54]. Though much work has been
done on VM formation, the substantial cellular and
molecular mechanisms underlying the effects of hyp-
oxia in the pathogenesis of VM in GBM remain largely
elusive.
Clinical-translational advances in the treatment of
GBM and future prospects of VM as a therapeutic
target
As highlighted by the multitude of signaling pathways
discussed above, comprehensive treatments are indis-
pensable for the control of highly aggressive tumors.
Consequently, the understanding of how mono-therapies
coordinate to optimize therapeutic outcomes may help
to further the understanding of GBM. To achieve this
goal, mounting efforts have focused on identifying the
related mechanisms. The highly plastic phenotype, suffi-
cient blood perfusion and an adequate nutrient supply
are critical for sustaining continual progression of neo-
plasms. However, the regulatory mechanisms that create
these conditions may provide the key to control the
process: the tumor cells, along with their stem cells and
pericytes, construct their habitat with the assistance of
autocrine or paracrine signals, which in turn influence
the tumor properties. To obtain the maximum neoplas-
tic effect, a tumor must implement all of the above strat-
egies for the positive reinforcement of growth. Hence,
the available tumor therapies, on one hand, are aimed at
targeting tumor cells and their progenitor CSCs; and on
the other hand, are aimed at simultaneously suppressing
the remodeling of the microenvironment and related
molecules. For optimal design of therapeutics, the removal
or disruption of tumor-related cells, the elimination of es-
sential oxygen and energy supply and the intervention of
underlying signaling cascades should all be taken into
consideration.
Aside from tumor cell-targeting therapy, the mechanisms
of angiogenesis and vascularization are perplexing enough
to elicit detailed interpretation. Because the conventional
anti-angiogenesis strategies exhibited disappointing results
in cumulative clinical trials, several other paradigms abouttumor blood supply have emerged, including VM, which
has drawn intense controversy since it was first described
in 1999. Since then, evidence has begun to accumulate to
validate the existence and significance of this novel circula-
tory structure [1,17,56,57], and meta-analysis has validated
the association between VM and poor prognosis [58]. A
variety of staining methods from physicochemical dyeing to
immunofluorescence techniques have been utilized to re-
veal the histological features and origins of VM; multidis-
ciplinary approaches have been applied for understanding
the aberrant gene transcription and protein translation as-
sociated with VM. On the basis of these studies, the func-
tions of a number of genes have been validated in VM, and
several molecular pathways have been demonstrated that
could provide potential targets for therapy.
Among the potential therapies for VM, anti-angiogen-
esis by the VEGF mono-antibody Bevacizumab showed
minimal efficacy and enhanced tumor invasiveness trig-
gered by hypoxia induction, which may be partially due
to VM [33]; and the potent angiogenesis inhibitor Endo-
star did not affect GBM VM formation [59]. While ther-
apies aimed at classical anti-angiogenesis have shown
limited effects, the VM associated mechanisms offered
new insights. A handful of preclinical studies suggest
that specific compounds affecting components of the
previously described vascular, embryonic or hypoxia
pathways in tumor cells can inhibit VM formation in
xenograft tumor models. VEGFR-2 kinase inhibitors
SU1498 and AZD2171 have been shown to reduce VM
channel formation in GBM cell lines in vitro and in vivo,
concurrent with a reduction in chemotaxis, proliferation
and tumorigenicity [26]. Likewise, the MMP inhibitor
chemically modified tetracycline [28] and the TGF inhibi-
tor isoxanthohumol [60] downregulate VE-cadherin,
EphA2, laminin5γ2 and MMPs and impair VM formation.
Lidamycin suppresses tubular structure in a dose-
dependent manner, potentially through an apoptosis-re-
lated mechanism [61]; while targeting of the RTK/PI3K/
Akt pathway enhances the cytotoxic effect of radiation and
temozolomide in malignant glioma cells [49].
The increasing abundance of targeted techniques,
such as gene knockdown technology, delineates a tan-
gible realization of the potential for counteracting
tumor-related mechanisms, which should eventually
lead to effective treatments for GBM and other human
diseases. In addition, newly devised targeted drug
delivery systems circumvent multidrug resistance and
demonstrate an enhanced chemotherapeutic efficacy
[62,63] . The use of strategies targeting multiple signal-
ing pathways in a combinatorial manner may lead to
increased therapeutic efficiency; and studies on VM as
a novel and distinct circulatory system will certainly
contribute significantly to the future development of
anti-tumor treatment regimens.
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